Leerink Affirms Celgene (CELG) at 'Market Perform'; Doesn't see Strong Mongersen Phase 2 Data Translating to Phase 3

Celgene Announces Interim Topline Data from Trial of Investigational Oral GED-0301 in Patients with Active Crohn’s Disease

Data show endoscopic improvement and clinical response and remission at week 12

Safety and tolerability consistent with previous studies

Results expected to be presented at upcoming medical meetings

SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) today announced interim topline data from a randomized, double-blind, multicenter, exploratory phase 1b study evaluating the effects of oral GED-0301 (mongersen) on both endoscopic and clinical outcomes in patients with active Crohns disease.

The trial, CD-001, is an ongoing study evaluating... More